Immune system modulation via allergen-specific desensitization (null)

"Immune system modulation via allergen-specific desensitization" does not refer to a single molecule or receptor but rather describes the therapeutic process known as **allergen-specific immunotherapy**. This approach involves the gradual introduction of increasing doses of an allergen to induce immune tolerance. The underlying mechanisms include early desensitization effects on mast cells and basophils; induction and expansion of regulatory T cells that secrete IL‑10 and TGF‑β; suppression of effector Th2 responses; reduction in IgE production with increased production of blocking antibodies such as IgG4 and IgA by B cells; decreased migration and activation of eosinophils, basophils, and mast cells in tissues. These changes collectively shift the immune response from an allergic phenotype toward one characterized by tolerance. The process is not mediated by interaction with any single protein or receptor but rather through complex cellular interactions within the adaptive immune system. Drugs are allergens used for desensitization, as this is not a molecular target. There are no direct biomarkers specific to this "target"; however, in practice, allergen-specific IgE/IgG4 levels or Treg activity may be monitored as part of therapy assessment. This entry is **not suitable** as a canonical therapeutic target because it refers to an entire biological process rather than a discrete druggable entity such as a receptor or enzyme.

Other names

Allergen-specific immunotherapyAllergen immunotherapyDesensitization therapySpecific immunotherapy

null